Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.39 |
| ▸ | TYR | P14679 | 2/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.38 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28838403 | 0.86 | GRM5 (0.37) | GRM5GRM2GRM8GRM4GRIA1 | |
| SCHEMBL5282402 | 0.84 | GRIA1 (0.51) | GRM5GRIA1GRIK1GRIA2GRIA3 | |
| SCHEMBL9694567 | 0.81 | ALDH1A1 (0.33) | — | |
| SCHEMBL4348692 | 0.77 | ADRA1D (0.37) | — | |
| D-Glutamate SCHEMBL28865803 | 0.75 | GRM8 (0.51) | GRM5GRM2GRM8GRM4GRIA1 | |
| SCHEMBL2983409 | 0.74 | ADRA1D (0.34) | — | |
| SCHEMBL2930015 | 0.74 | HASPIN (0.35) | — | |
| SCHEMBL17371774 | 0.74 | FABP4 (0.50) | — | |
| SCHEMBL337058 | 0.73 | TYMP (0.37) | — | |
| SCHEMBL2899641 | 0.73 | APEX1 (0.48) | GRIA1GRIA2GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2056 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | claimed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | claimed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | claimed |
| EP-3157572-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| CN-106170553-A | Modified nucleic acid molecules and uses thereof | 现代治疗公司 | 2016-11-30 | — | — | CN | claimed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | claimed |
| EP-3080289-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-10-19 | — | — | EP | claimed |
| WO-2016043661-A1 | MODIFIED PEPTIDE NUCLEIC ACIDS AND THEIR USE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-03-24 | — | — | WO | claimed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | claimed |
| EP-2931319-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | claimed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | claimed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | claimed |
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | claimed |
| EP-4748381-A2 | PRODUCTS AND COMPOSITIONS | Silence Therapeutics GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748382-A2 | PRODUCTS AND COMPOSITIONS | Silence Therapeutics GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| CN-122095091-A | DsRNA for inhibiting LPA gene expression and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2004064737-A2 | THERAPEUTICS COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20020137135-A1 | Novel NPG-1 gene that is differentially expressed in prostate tumors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC., A MASSACHUSETTS CORPORATION | 2002-09-26 | — | — | US | disclosed |
| US-6287777-B1 | SEVERAL GENES EXPRESSED DIFFERENTIALLY BETWEEN THE HUMAN PROSTATE CARCINOMA CELL LINES LNCAP AND PC-3, WHICH ARE ANDROGEN-DEPENDENT AND ANDROGEN-INDEPENDENT, RESPECTIVELY, HAVE NOW BEEN ISOLATED. ONE OF THESE GENES, DESIGNATED NPG-1. | BETH ISRAEL DEACONESS MEDICAL CENTER | 2001-09-11 | — | — | US | disclosed |